Tiziana Life Sciences announces $4 million grant awarded by NIH to study anti-CD3 in Alzheimer’s disease: New York Saturday, September 21, 2024, 14:00 Hrs [IST] Tiziana Life Sci ...

Alzheimer’s disease is the most common form of dementia, affecting more than 6 million people in the United States alone. Despite extensive research, effective treatments remain limited, and the need ...

In 1-year-old infants with challenge-proven IgE-mediated egg allergy, longitudinal impairment was observed in IFNγ and FoxP3 induction.

Anti-CD3 positive cells in epithelial and interstitial tissues The aim of the project was to quantify the distribution of anti-CD3 positive cells in and around the epithelial areas of prostate ...

An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...

Initial data from an ongoing phase I study showed signs of anti-tumor activity for its investigational ENPP3 x CD3 bispecific antibody XmAb819 in patients with clear cell renal cell carcinoma.

Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.